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ABSTRACT
Background: Insulin resistance (IR) is frequently recognized in patients with
uremia, and it is thought that IR has a basic role in the pathogenesis of cardiovascular
disease.
Objective: To evaluate the effect of IR on cardiovascular risk in non-diabetic
patients receiving hemodialysis (HD).
Methods: We performed a cross-sectional observational study that comprised
86 non-diabetic patients receiving HD (95 men; mean [SD] age, 46.4 [10.8] years;
ge range, 35–60 years) who had been receiving HD for 7.3 (3.5) years. Demographic
ariables and laboratory values were recorded. Insulin resistance was determined using
he Homeostatic Model Assessment (HOMA), and the left ventricular mass index
LVMI) was calculated via echocardiography.
Results: According to HOMA-IR levels, patients were categorized as having
R (HOMA-IR score 2.5; n  53) or not having IR (HOMA-IR score 2.5; n 
133). Insulin resistance was determined in 28.4% of study patients. Compared with
the non-IR group, the IR group had been receiving HD longer; had greater body
mass index; and had higher serum creatinine, uric acid, triglyceride, insulin, and
C-reactive protein concentrations, leukocyte count, and LVMI (P  0.05). Patients
with increased LVMI had significantly higher body mass index, systolic blood
pressure, serum cholesterol and C-reactive protein concentrations, and HOMA score.
At multivariate analysis, systolic blood pressure (  0.22; P  0.03) and HOMA
score (  0.26; P  0.01) affected LVMI.
Conclusions: Insulin resistance and hypertension are independent risk factors
for left ventricular hypertrophy in non-diabetic patients with uremia who are receiv-
ing HD. Further studies are needed to indicate the benefits of improving IR for
cardiovascular mortality in this subgroup of patients with uremia. (Curr Ther Res Clin
Exp. 2012;73:165–173) © 2012 Published by Elsevier HS Journals, Inc.
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Current Therapeutic ResearchINTRODUCTION
The process of cardiovascular damage starts very early in patients with chronic kidney
disease, and the damage progresses rapidly with advanced kidney dysfunction.1,2
Insulin resistance (IR) occurs frequently in patients with uremia, and it is thought
that it has a basic role in the pathogenesis of cardiovascular disease in end-stage renal
disease (ESRD).3–7 Insulin resistance may be involved in the pathogenesis of athero-
sclerosis, hypertension, and dyslipidemia. Moreover, in patients with ESRD, there is
premature aging of the vascular tree. Endothelial dysfunction in patients receiving
dialysis therapy has negative effects on left ventricular structure and function.7 The
elationship between IR, which is a proinflammatory state, and left ventricular mass
ndex (LVMI) has not been investigated in patients receiving hemodialysis (HD). To
ate, no study is available in the literature that examined the possible relationship
etween IR and LVMI in non-diabetic patients receiving HD.
METHODS
Patients
We performed a cross-sectional observational study in patients receiving HD to
valuate the effect of IR on LVMI. The study comprised 186 non-diabetic patients (95
en; mean [SD] age, 46.4 [10.8] years; age range, 35–60 years) who had been
eceiving HD for 7.3 (3.5) years. Inclusion criteria were age 18 years and duration
f previous dialysis 6 months. Exclusion criteria were diabetes mellitus, cardiac
ailure, acute myocardial infarction, comorbidity with malignancy, and acute infective
isorders in the 3 months before inclusion in the study. No patients were obese (body
ass index, 20–29), and none were malnourished. The causes of ESRD were hyper-
ension in 52 patients (28%), chronic glomerulonephritis in 31 patients (16%),
olycystic kidney disease in 26 patients (14%), interstitial nephritis in 17 patients
10%), and other or unknown cause in 60 patients (32%). Hemodialysis was per-
ormed 3 times a week (4 hours per session), with an average blood flow rate of 300
o 350 mL/min, dialysate flow of 500 mL/min, and mean Kt/V maintained at 1.2
uring the study. The study protocol was approved by the local scientific ethics
ommittee, and informed consent was obtained from each patient.
Demographic variables (age, sex, cause of ESRD, duration of HD, and anthropo-
etric measurements) were recorded. After an overnight fast in a mid-week day,
re-dialysis blood samples were drawn for analysis of laboratory values (Table I). The
nsulin level was measured via electroimmunoassay using a Modular Analytics E170
nsulin kit (Roche Diagnostics GmbH, Mannheim, Germany), and glucose was
easured via spectrophotometry using a hexokinase assay. Insulin resistance was
haracterized using the Homeostasis Model Assessment Method (HOMA-IR) and
alculated as fasting insulin (U/mL)  fasting glucose (mmol/L)/22.5.8 Patients were
classified as HOMA-IR() if their HOMA score was 2.5. Demographic, clinical,
and biochemical characteristics of these patients are given in Table I. Nursing staff
measured systolic and diastolic blood pressure using standard mercury sphygmoma-
nometers on the right arm of seated participants who had rested for at least 5 minutes.
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S. Karakan et al.Weight, height, and waist circumference were determined for each patient. Waist
ircumference was measured at the narrowest diameter between the costal margin and
he iliac crest. Height (in meters) and weight (in kilograms) were measured with the
atient dressed in light clothing and without shoes. Several indicators of adiposity
ere calculated from these measurements. Body mass index (BMI) was calculated as
Table I. Demographic, clinical, and biochemical characteristics of the study patients.
Variable Value
No. of patients, male/female 95/91
Age, y 46.4 (10.8); 35–60
lood pressure, mm Hg
Systolic 124.7 (28.1); 98–162
Diastolic 79.1 (13.7); 60–110
ody mass index 25.2 (4.9); 20–30
emodialysis duration, y 7.3 (3.5); 3.8–10.8
enal diagnosis, No. (%)
Hypertension 52 (28)
Chronic glomerulonephritis 31 (16)
Polycystic kidney disease 26 (14)
Interstitial nephritis 17 (10)
Other or unknown 60 (32)
lood urea nitrogen, mg/dL 51.7 (13.5); 26–64
reatinine, mg/dL 8.4 (2.5); 5.3–10.8
lucose, mg/dL 88.1 (32.3); 60–113
ric acid, mg/dL 6.0 (1.9); 3.7–8.0
otal cholesterol, mg/dL 185.7 (50.0); 96.0–267.0
ow-density lipoprotein cholesterol, mg/dL 97.9 (64.7); 80–130
riglycerides, mg/dL 213.6 (198.9); 51.0–442.0
-reactive protein, mg/dL 10.9 (10.1); 0–43
nsulin, IU/L 12.3 (11.4); 0.9–23.7
emoglobin, g/dL 11.4 (1.4); 8.3–12.8
eukocyte count, 103/mL 7.4 (2.4); 3.5–9.8
latelet count (/mL) 254.6 (74.2); 115–334
t/V, wk 1.96 (0.44)
jection fraction, % 48.7 (8.4); 20–60
eft ventricular internal dimension, mm 151.8 (41.6)
eft ventricular mass index, g/m2 137.6 (24.1); 113–163
HOMA-IR score 2.6 (1.8); (0.8–4.4)
Unless otherwise indicated, values are given as mean (SD); range.eight in kilograms divided by the square of the height in meters.
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Current Therapeutic ResearchEchocardiography
Echocardiographic examinations were performed using 2-dimensional, M-mode,
ulse-wave Doppler, and tissue Doppler echocardiography by using a sonographic
ystem (Hewlett Packard Sonos 7500; Philips Medical Systems, Andover, Massachu-
etts) with a 2.8-MHz probe. Conventional echocardiography measurements (M-
ode and conventional pulse-wave Doppler) were determined according to guidelines
f the American Society of Echocardiography.9 Left ventricular mass (LVM) was
calculated using the Devereux formula10: LVM (g)  0.8  [1.04  (IVST  LVID 
LPWT)3 – (LVID)3 0.6], where IVST interventricular septal thickness, LVID
left ventricular internal dimension, and LPWT  left posterior wall thickness. The
left ventricular mass index (LVMI) was calculated using the formula LVM/
(height)2.7.10 The ratio of early diastolic–late diastolic mitral inflow velocities was
easured. Tissue Doppler imaging was performed using the apical 4-chamber view,
nd the images were digitized. Myocardial velocity profiles of the lateral mitral
nnulus were obtained by placing a 6-mm sample at the junction of the mitral
nnulus and the lateral myocardial wall.
Statistical Analyses
Statistical analysis was performed using SPSS for Windows (version 13.0; SPSS,
nc, Chicago, Illinois). All data are given as mean (SD). Geometric means for all
og-normally distributed continuous variables were calculated and reported with 95%
onfidence intervals, and duration of HD as median values and ranges. If possible,
ata were logarithmically transformed to achieve a normal distribution. Normally
istributed measurements were evaluated using an independent sample t test and
eported as mean (SD), and nonnormally distributed data were evaluated using the
ann-Whitney U test and reported as median and minimal–maximal values. Factors
howing a linear correlation with insulin resistance (P  0.05) were included in the
nalysis. Pearson or Spearman coefficients were used. The Mann-Whitney rank sum
test or Student t test were used for statistical analysis to compare differences
etween groups. Multiple regression analysis was used to determine independent
actors affecting the dependent variable. P  0.05 was considered significant.
RESULTS
Patient Characteristics and Comparison Between Patients With
and Without IR
In the present study, 186 non-diabetic patients receiving HD were assessed for IR.
he median (interquartile range) HOMA-IR score was 3.33 (1.94) (range, 1.39–
.27). According to HOMA-IR scores, patients were classified as having IR
HOMA-IR score2.5; n 53) or not having IR (HOMA-IR score2.5; n 133).
nsulin resistance was found in 28.4% of all study patients. The IR group, compared
ith the non-IR group, had been receiving HD longer (6.8 [3.2] years vs 4.2
1.1]years; P  0.01); had greater BMI (26.1 [3.9] vs 24.3 [4.3]; P  0.01); had
igher serum concentrations of creatinine (8.3 [2.1] mg/dL vs 7.1 [2.7] mg/dL; P 
.04), uric acid (6.8 [1.2] mg/dL vs 5.6 [1.9] mg/dL; P  0.01), triglycerides (218.2
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S. Karakan et al.[42.2] mg/dL vs 187.4 [36.9] mg/dL; P  0.01), insulin (16.4 [7.2] IU/L vs 8.24
[2.61] IU/L; P  0.01), and C-reactive protein (CRP) (8.4 [7.2] mg/dL vs 4.7 [4.1]
mg/dL; P  0.03); had a higher leukocyte count (8.6 [1.8]  103/mL vs 7.8
[2.1] 103/mL; P  0.02); and had greater LVMI (146.3 g/m2 [34.2] vs 132.2 [36.9]
g/m2; P  0.01) (Table II).
Correlations Between IR and LVMI
Mean (SD) LVMI was calculated as 137.6 (24.1). Data for LVMI were not normally
istributed. Pearson correlation analysis was performed, and BMI (r  0.48; P 
0.01), systolic blood pressure (r  0.62; P  0.04), and HOMA score (r  0.49;
 0.03) were positively correlated with LVMI, whereas hemoglobin (r  0.41;
P  0.02) and ejection fraction (r  0.29; P  0.04) were negatively correlated
ith LVMI. Patients were divided into 2 groups according to median (SD) LVMI
alue (137.6 [24.1] g/m2). Group 1 had low values (125.7 [24] g/m2), and group 2
had high values (142.5 [16.8] g/m2). Compared with patients in group 1, those in
group 2 had significantly higher BMI (P  0.01), systolic blood pressure (P  0.02),
and serum total cholesterol (P  0.04) and CRP (P  0.03) concentrations, and
HOMA scores (P  0.03).
At multiple linear regression analysis, we further explored age; HD duration;
creatinine, uric acid, total cholesterol, CRP, and insulin concentrations; and HOMA
scores as independent variables. It become apparent that systolic blood pressure ( 
0.22; P  0.03) and HOMA score (  0.26; P  0.01) affected LVMI (Table III).
DISCUSSION
Insulin resistance develops inevitably in patients with impaired renal function, and a
Table II. Comparison of clinical and biochemical variables in patients with and without IR.
Variable With IR (n  53) Without IR (n  133) P
Age, y 48.9 (15.4) 47.7 (13.3) NS
No. of patients, male/female 21/32 74/59 NA
Duration of HD, y, median (SD) 6.8 (3.2) 4.2 (1.1) 0.01
Body mass index 26.2 (3.9) 24.3 (4.3) 0.01
Creatinine, mg/dL 8.3 (2.1) 7.1 (2.7) 0.04
Uric acid, mg/dL 6.8 (1.2) 5.6 (1.9) 0.01
Triglycerides, mg/dL 218.2 (42.2) 187.4 (36.9) 0.01
C-reactive protein, mg/L 8.4 (7.2) 4.7 (4.1) 0.03
Leukocyte count, 103/mL 8.6 (1.8) 7.8 (2.1) 0.02
VMI, g/m2 146.3 (34.2) 132.2 (36.9) 0.01
HD  hemodialysis; IR  insulin resistance; LVMI  left ventricular mass index; NA  not applicable;
NS  not significant.
Unless otherwise indicated, values are given as mean (SD).high prevalence of IR has been found in patients with ESRD.11–14 This study revealed
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Current Therapeutic Researchthat IR, as measured via HOMA, is related to cardiovascular risks in non-diabetic
patients receiving HD.
Various techniques have been previously used to assess IR and glucose tolerance in
renal disease, including euglycemic insulin clamp, HOMA-IR score, oral or intrave-
nous glucose tolerance testing, and fasting insulin concentrations.15–20 We found the
ean HOMA-IR score was 1.46 in non-diabetic patients receiving HD. This was
onsistent with the literature: 3 different studies reported mean HOMA-IR scores as
.16, 1.23, and 1.40, respectively.21–23 Our result is in agreement with the finding
f Ramos et al.24 Recent evidence has suggested that inflammation might be an
mportant mechanism contributing to IR.25 In the present study, inflammatory
markers such as serum CRP and leukocyte count were correlated with the presence of
IR. Chronic inflammatory response may be another mechanism. Cytokines secreted
from adipocytes such as tumor necrosis factor- and leptin were considered to have
an important role in the development of IR in patients with uremia.26 Insulin
resistance is thought to cause endothelial inflammation, primarily via nitric oxide
(NO) depletion and increased reactive oxygen species.27–29 Subclinical elevation of
serum CRP concentration in patients receiving HD may reflect microvascular in-
flammation induced by IR, which is likely to lead to microcirculatory disturbances in
the heart. The present study also documents the close relationship between IR and
uric acid concentration. Hyperuricemia has an important role in IR via its effect in
lowering the NO level and also possibly by a direct effect of uric acid on adipocytes.30
Our analyses suggested that IR was the predominant determinant of left ventric-
lar mass. Tissue resistance to insulin is the primary cause of IR in ESRD.31 Insulin
Table III. Stepwise linear regression analysis with left ventricular mass index as depen-
dent variable.*
Independent Variable
Left Ventricular Mass Index
 P
Age, y 0.13 NS
HD duration, y 0.12 NS
Blood pressure, mm Hg
Systolic 0.22 0.03
Diastolic 0.19 NS
Total cholesterol, mg/dL 0.191 NS
LDL cholesterol, mg/dL 0.16 NS
C-reactive protein, mg/L 0.17 NS
HOMA 0.26 0.01
Ejection fraction, % 0.53 NS
HOMA  Homeostatic Model Assessment; LDL  low-density lipoprotein; NS  not significant.
*n  186; r2  0.41.esistance may be linked to vascular endothelial dysfunction, which may be largely a
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S. Karakan et al.consequence of acquired defects of NO synthesis and intracellular signaling.32 En-
othelial dysfunction linked to IR is believed to take part in microcirculatory
isturbances in the heart and to compromise myocardial adenosine triphosphate
ynthesis in patients with ESRD.33–36 Because myocardial adenosine triphosphate
ontent deeply affects left ventricular wall motion, a combination of IR and this
erangement may aggravate left ventricular dysfunction. At multiple regression
nalysis, LVMI was strongly associated with IR in study patients. Understanding the
elationship between IR and impaired cardiac functions is important for establish-
ent of congestive heart failure in non-diabetic patients receiving HD.
CONCLUSIONS
IR assessed via HOMA-IR is closely associated with cardiovascular risk in non-
diabetic patients receiving HD. Inasmuch as IR is a reversible risk factor, reduction
of IR may be a potential therapeutic target. However, randomized controlled studies
are needed to clarify whether enhancing insulin sensitivity could improve cardiac
performance and subsequently reduce left ventricular hypertrophy and cardiovascular
mortality in ESRD.
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